

JUN - 6 2003

K030965

**Section 3**  
**Control Plasma LMW Heparin - 510(k) Summary**  
**(Summary of Safety and Effectiveness)**

**Submitted by:**

Instrumentation Laboratory Company  
113 Hartwell Avenue  
Lexington, MA 02421  
Phone: 781-861-4467  
Fax: 781-861-4207

**Contact Person:**

Carol Marble, Regulatory Affairs Director  
Phone: 781-861-4467 / Fax: 781-861-4207

**Summary Prepared:**

March 26, 2003

**Name of the device:**

Control Plasma LMW Heparin

**Classification names:**

Common Name	Plasma, Coagulation Control
Product Code	GGN
Regulation Number	864.5425
Classification	Class II

**Identification of predicate devices:**

K002400 Assess Low and High Heparin Controls

NOTE: These control levels were 510(k) cleared as part of analyzer systems, most recently the ACL Advance.

**Description of the device/intended uses:**

Control Plasma LMW Heparin is an *in vitro* diagnostic quality control material intended for use with chromogenic heparin assays to assess precision and accuracy at heparin low and high levels.

**Statement of Technological Characteristics of the Device Compared to Predicate Devices:**

Control Plasma LMW Heparin is substantially equivalent in intended use to the predicate controls: Assess Low and High Heparin Controls.

**Summary of Performance Data:**

A precision study was performed with Control Plasma LMW Heparin (Low and High Levels) over multiple days with multiple runs (n=60) using specific lots of IL reagents on IL instrumentation:

Description	Mean IU/mL	Within Run %CV	Between Run %CV	Total CV%
Low Level	0.42	3.81	1.70	4.65
High Level	0.75	2.26	0.71	3.34



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

JUN - 6 2003

Ms. Carol Marble  
Regulatory Affairs Manager  
Instrumentation Laboratory Company  
101 Hartwell Avenue  
Lexington, Massachusetts 02421-3125

Re: k030965  
Trade/Device Name: Control Plasma LMW Heparin  
Regulation Number: 21 CFR § 864.5425  
Regulation Name: Multipurpose System for in vitro coagulation studies  
Regulatory Class: II  
Product Code: GGN, KFF  
Dated: May 19, 2003  
Received: May 30, 2003

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 –

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Office of In Vitro Diagnostic Device Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

